<DOC>
	<DOCNO>NCT02219802</DOCNO>
	<brief_summary>Rationale : Compared balloon angioplasty , implantation bare metal stent ( BMS ) drug elute stent ( DES ) show reduce repeat target lesion revascularization primary percutaneous coronary intervention ( PPCI ) . However , result reduction mortality recurrent myocardial infarction . Furthermore , concern occurrence stent thrombosis . The PAPPA-pilot study , evaluate safety feasibility use drug-coated balloon ( DCB ) strategy PPCI , show good short- long-term clinical result , sustain safety efficacy 12 month follow-up . To date little known long-term effect treatment modality STEMI . Besides , angiographic follow-up great clinical importance give insight treat infarct lesion ass functional angioplasty result . Objective : This randomized control , non-inferiority trial mainly design prospectively assess safety efficacy CE-marked paclitaxel-eluting balloon strategy vs. third generation DES set ST-elevation myocardial infarction ( STEMI ) .</brief_summary>
	<brief_title>Drug-coated Balloon Versus Drug-eluting Stent Acute Myocardial Infarction</brief_title>
	<detailed_description>Rationale : Compared balloon angioplasty , implantation bare metal stent ( BMS ) drug elute stent ( DES ) show reduce repeat target lesion revascularization primary percutaneous coronary intervention ( PPCI ) . However , result reduction mortality recurrent myocardial infarction . Furthermore , concern occurrence stent thrombosis . The PAPPA-pilot study , evaluate safety feasibility use drug-coated balloon ( DCB ) strategy PPCI , show good short- long-term clinical result , sustain safety efficacy 12 month follow-up . To date little known long-term effect treatment modality STEMI . Besides , angiographic follow-up great clinical importance give insight treat infarct lesion ass functional angioplasty result . Objective : This randomized control , non-inferiority trial mainly design prospectively assess safety efficacy CE-marked paclitaxel-eluting balloon strategy vs. third generation DES set ST-elevation myocardial infarction ( STEMI ) . Study design : This prospective , single center , non-inferiority , randomize control trial . Study population : All patient present STEMI suitable PPCI . Intervention : PPCI perform accord current guideline . After thrombus aspiration pre-dilatation , randomization DCB strategy ( bail-out stenting indicate ) DES do 1:1 ratio . Concomitant medication administer accord current standard . Control coronary angiography , include measurement fractional flow reserve ( FFR ) treat lesion ( ) , perform 9 month . Main study parameters/endpoints : The main study parameter fractional flow reserve 9 month follow-up . Secondary study parameter include cardiac death , recurrent myocardial infarction target vessel area ischemia drive target lesion revascularisation 9 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Acute myocardial infarction eligible primary PCI : &gt; 20 min chestpain least 1 mm STelevation least two contiguous lead , new leave bundle branch block true posterior myocardial infarction ( confirm ECG echocardiography ) Reperfusion expect feasible within 12 hour onset complaint Infarct relate artery eligible PPCI : De novo lesion native coronary artery Referencevessel diameter ≥ 2.5mm ≤ 4mm Without severe calcification Without diameter stenosis &gt; 50 % ( visual assessment ) thrombus aspiration predilatation . The protocol require visualization , thrombus aspiration predilatation culprit lesion inclusion . Age &lt; 18 year &gt; 75 year History myocardial infarction Known contraindication/resistance bivalirudin , fondaparinux , heparin , aspirin , prasugrel and/or ticagrelor . Participation another clinical study , interfere protocol Uncertain neurological outcome e.g . resuscitation Intubation/ventilation Cardiogenic shock prior randomization Known intracranial disease ( mass , aneurysm , AVM , hemorrhagic CVA , ischemic CVA/TIA &lt; 6 month prior inclusion ischemic CVA permanent neurological deficit ) Gastrointestinal / urinary tract bleed &lt; 2 month prior inclusion Refusal receive blood transfusion Planned major surgery within 6 week Stent implantation &lt; 1 month prior inclusion Expected mortality cause within next 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Drug-coated balloon</keyword>
	<keyword>Drug-eluting stent</keyword>
</DOC>